StratumSkin science, cited
Ingredient Index

Vitiligo

Ruxolitinib

Topical JAK inhibitor (Opzelura)

Overall grade BTypical strength 1.5% cream, twice daily2 sources

The first topical drug with genuine randomised-trial evidence for actually restoring pigment in vitiligo, not just slowing its spread. Roughly twice as many people regained visible facial colour on ruxolitinib as on a plain vehicle cream over six months, with results still building at a year. It's a JAK inhibitor, which brings an FDA boxed warning inherited from oral drugs in the same class — a conversation to have with a dermatologist, not a self-prescribing decision.

Claim by claim

BFacial repigmentation (F-VASI75) at 24 weeksAbout 30% of patients reached 75% improvement in facial pigmentation, against about 13% on vehicle cream, across two identical phase 3 trials.
CFacial repigmentation with continued useIn the one-year open-label extension that followed, roughly half of patients reached that same 75% facial improvement bar — a promising trend without a placebo group left to compare it against by that point.
AApplication-site side effectsAcne and itching where the cream was applied were the most common reactions, each affecting roughly 1 in 20 users. Generally mild.
ABoxed warning for serious risksCarries the same FDA boxed warning as oral JAK inhibitors — serious infections, cardiovascular events, blood clots and cancer — a class-wide warning based mainly on oral-drug data, not a finding specific to the topical vitiligo trials.

References

  1. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine, 2022.BTwo identical phase 3 RCTs (TRuE-V1, TRuE-V2), ~300 patients each, age 12 and up, nonsegmental vitiligo, 2:1 randomisation to ruxolitinib 1.5% cream vs vehicle, 24-week controlled period·Funded and run by Incyte, which developed ruxolitinib cream and markets it as Opzelura — an industry-sponsored registration trial, though independently peer-reviewed in NEJM and the basis for FDA approval. About 30% of ruxolitinib patients reached F-VASI75 at week 24 versus about 13% on vehicle; benefit kept building through a 52-week open-label extension that no longer had a placebo arm to compare against.PubMed 36260792DOI 10.1056/NEJMoa2118828
  2. U.S. Food and Drug Administration OPZELURA (ruxolitinib) cream — prescribing information, boxed warning and adverse reactions. FDA-approved drug label (DailyMed), 2024.AOfficial prescribing information·The boxed warning for serious infections, increased mortality, malignancy, major cardiovascular events and thrombosis is a class warning applied to every JAK inhibitor, drawn mainly from oral-drug data, not a finding specific to the topical vitiligo trials. In those trials specifically, the most common reactions were application-site acne (6%) and itching (5%).Read the source

Related condition hub

Vitiligo

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.